BR112022010227A2 - Proteína de fusão gdf15 de ação prolongada e composição farmacêutica compreendendo a mesma - Google Patents
Proteína de fusão gdf15 de ação prolongada e composição farmacêutica compreendendo a mesmaInfo
- Publication number
- BR112022010227A2 BR112022010227A2 BR112022010227A BR112022010227A BR112022010227A2 BR 112022010227 A2 BR112022010227 A2 BR 112022010227A2 BR 112022010227 A BR112022010227 A BR 112022010227A BR 112022010227 A BR112022010227 A BR 112022010227A BR 112022010227 A2 BR112022010227 A2 BR 112022010227A2
- Authority
- BR
- Brazil
- Prior art keywords
- gdf15
- fusion protein
- acting
- pharmaceutical composition
- long
- Prior art date
Links
- 102100040896 Growth/differentiation factor 15 Human genes 0.000 title abstract 11
- 101000893549 Homo sapiens Growth/differentiation factor 15 Proteins 0.000 title abstract 11
- 108020001507 fusion proteins Proteins 0.000 title abstract 8
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 5
- 102000037865 fusion proteins Human genes 0.000 abstract 6
- 239000003814 drug Substances 0.000 abstract 4
- 208000030159 metabolic disease Diseases 0.000 abstract 3
- 229940124597 therapeutic agent Drugs 0.000 abstract 3
- 208000008589 Obesity Diseases 0.000 abstract 2
- 239000004480 active ingredient Substances 0.000 abstract 2
- 238000002648 combination therapy Methods 0.000 abstract 2
- 235000020824 obesity Nutrition 0.000 abstract 2
- 230000037396 body weight Effects 0.000 abstract 1
- 206010061428 decreased appetite Diseases 0.000 abstract 1
- 239000000539 dimer Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 238000000338 in vitro Methods 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 230000003880 negative regulation of appetite Effects 0.000 abstract 1
- 230000001766 physiological effect Effects 0.000 abstract 1
- 239000013636 protein dimer Substances 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/495—Transforming growth factor [TGF]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/90—Fusion polypeptide containing a motif for post-translational modification
- C07K2319/91—Fusion polypeptide containing a motif for post-translational modification containing a motif for glycosylation
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Genetics & Genomics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Obesity (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Child & Adolescent Psychology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Plant Pathology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20190153680 | 2019-11-26 | ||
| PCT/KR2020/016842 WO2021107603A2 (en) | 2019-11-26 | 2020-11-25 | Long-acting gdf15 fusion protein and pharmaceutical composition comprising same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112022010227A2 true BR112022010227A2 (pt) | 2022-09-13 |
Family
ID=76130664
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112022010227A BR112022010227A2 (pt) | 2019-11-26 | 2020-11-25 | Proteína de fusão gdf15 de ação prolongada e composição farmacêutica compreendendo a mesma |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20230002460A1 (https=) |
| EP (1) | EP4065597A4 (https=) |
| JP (1) | JP2023503472A (https=) |
| KR (1) | KR20210065057A (https=) |
| CN (1) | CN114729020A (https=) |
| AU (1) | AU2020394255A1 (https=) |
| BR (1) | BR112022010227A2 (https=) |
| CA (1) | CA3161302A1 (https=) |
| MX (1) | MX2022006173A (https=) |
| WO (1) | WO2021107603A2 (https=) |
| ZA (1) | ZA202204624B (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN117750968A (zh) * | 2021-05-21 | 2024-03-22 | 株式会社柳韩洋行 | 用于预防或治疗非酒精性脂肪性肝病或非酒精性脂肪性肝炎的包括生长分化因子-15变体的组合物 |
| CA3219645A1 (en) * | 2021-05-21 | 2022-11-24 | Yuhan Corporation | Composition for combination therapy comprising growth differentiation factor-15 variant and glucagon-like peptide-1 receptor agonist |
| US20240391971A1 (en) * | 2021-08-24 | 2024-11-28 | Sunshine Lake Pharma Co., Ltd. | Gdf15 fusion proteins and uses thereof |
| CN120530128A (zh) * | 2022-11-18 | 2025-08-22 | 株式会社柳韩洋行 | 双功能蛋白及其用途 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5288931A (en) * | 1991-12-06 | 1994-02-22 | Genentech, Inc. | Method for refolding insoluble, misfolded insulin-like growth factor-I into an active conformation |
| GB9912350D0 (en) * | 1999-05-26 | 1999-07-28 | European Molecular Biology Lab Embl | Modified cytokine |
| FI117667B (fi) * | 2001-07-05 | 2007-01-15 | Univ Zuerich | Farmaseuttinen koostumus, joka soveltuu käytettäväksi ortopediassa ja hammaslääketieteessä |
| EP2441466B1 (en) | 2004-04-13 | 2014-07-23 | St Vincent's Hospital Sydney Limited | MIC-1 inhibiting agent |
| AU2012212047A1 (en) * | 2011-02-03 | 2013-08-22 | Xoma Technology Ltd. | Methods and materials for enhancing functional protein expression in bacteria |
| EP3683228A3 (en) * | 2012-01-26 | 2020-07-29 | Amgen Inc. | Growth differentiation factor 15 (gdf-15) polypeptides |
| US9161966B2 (en) * | 2013-01-30 | 2015-10-20 | Ngm Biopharmaceuticals, Inc. | GDF15 mutein polypeptides |
| KR101993714B1 (ko) * | 2013-01-30 | 2019-06-28 | 엔지엠 바이오파마슈티컬스, 아이엔씨. | 대사 장애를 치료하는데 이용하기 위한 조성물과 방법 |
| US9862752B2 (en) * | 2013-07-31 | 2018-01-09 | Amgen Inc. | Growth differentiation factor 15 (GDF-15) constructs |
| RU2017101436A (ru) * | 2014-06-24 | 2018-07-24 | Ново Нордиск А/С | Mic-1 слитные белки и их применение |
| AU2015296640B2 (en) * | 2014-07-30 | 2020-05-21 | Ngm Biopharmaceuticals, Inc. | Compositions and methods of use for treating metabolic disorders |
| US10603359B2 (en) * | 2014-10-30 | 2020-03-31 | Acceleron Pharma Inc. | Methods and compositions using GDF15 polypeptides for increasing red blood cells |
| EP3701969A1 (en) * | 2014-10-31 | 2020-09-02 | NGM Biopharmaceuticals, Inc. | Compositions and methods of use for treating metabolic disorders |
| US10336812B2 (en) * | 2016-05-10 | 2019-07-02 | Janssen Biotech, Inc. | GDF15 fusion proteins and uses thereof |
| KR101727506B1 (ko) * | 2016-07-14 | 2017-05-04 | 충남대학교 산학협력단 | Gdf15 단백질 또는 이를 암호화하는 폴리뉴클레오티드를 유효성분으로 함유하는 지방간의 예방 또는 치료용 약학적 조성물 |
-
2020
- 2020-11-25 CA CA3161302A patent/CA3161302A1/en active Pending
- 2020-11-25 BR BR112022010227A patent/BR112022010227A2/pt unknown
- 2020-11-25 JP JP2022530716A patent/JP2023503472A/ja active Pending
- 2020-11-25 CN CN202080081137.8A patent/CN114729020A/zh active Pending
- 2020-11-25 US US17/779,932 patent/US20230002460A1/en active Pending
- 2020-11-25 MX MX2022006173A patent/MX2022006173A/es unknown
- 2020-11-25 KR KR1020200160013A patent/KR20210065057A/ko active Pending
- 2020-11-25 AU AU2020394255A patent/AU2020394255A1/en active Pending
- 2020-11-25 EP EP20892374.8A patent/EP4065597A4/en active Pending
- 2020-11-25 WO PCT/KR2020/016842 patent/WO2021107603A2/en not_active Ceased
-
2022
- 2022-04-25 ZA ZA2022/04624A patent/ZA202204624B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN114729020A (zh) | 2022-07-08 |
| EP4065597A4 (en) | 2024-01-24 |
| EP4065597A2 (en) | 2022-10-05 |
| CA3161302A1 (en) | 2021-06-03 |
| WO2021107603A2 (en) | 2021-06-03 |
| AU2020394255A1 (en) | 2022-06-09 |
| US20230002460A1 (en) | 2023-01-05 |
| KR20210065057A (ko) | 2021-06-03 |
| WO2021107603A3 (en) | 2021-07-15 |
| JP2023503472A (ja) | 2023-01-30 |
| MX2022006173A (es) | 2022-06-14 |
| ZA202204624B (en) | 2023-11-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112022010227A2 (pt) | Proteína de fusão gdf15 de ação prolongada e composição farmacêutica compreendendo a mesma | |
| Molero et al. | Antidepressant efficacy and tolerability of ketamine and esketamine: a critical review | |
| PE20242299A1 (es) | Composiciones agonistas de gip/glp1 | |
| ES2393211T3 (es) | Uso de 2-aminotetralinas sustituidas para la fabricación de un medicamento para la prevención, alivio y/o tratamiento de diversos tipos de dolor | |
| Ossowska et al. | Blockade of the metabotropic glutamate receptor subtype 5 (mGluR5) produces antiparkinsonian-like effects in rats | |
| BRPI0507609A (pt) | combinações terapêuticas de anti-psicóticos atìpicos com antagonistas de fator de liberação de corticotropina | |
| BRPI0704238A (pt) | preventivo da doença de coccidiose e clostrìdica e/ou terapia para a doença de coccidiose e clostridica | |
| Liu et al. | Pharmacological hypothermia: a potential for future stroke therapy? | |
| BRPI0816317A2 (pt) | Método para tratar o estresse oxidativo e melhorar a memória de trabalho pela administração de pterostilbeno | |
| ZA202210355B (en) | Compositions and therapeutic uses of cannabidiol | |
| BRPI0512311A (pt) | uso de meloxicam em medicina veterinária para o tratamento de doenças inflamatórias dolorosas | |
| MX2021015338A (es) | Composicion que comprende pridopidina y un analogo de la misma para el tratamiento de la enfermedad de huntington y sintomas de la misma. | |
| BR112021017314A2 (pt) | Uso de extrato de elaeocarpus sylvestris | |
| BR112022016761A2 (pt) | Compostos de derivado de 1,3,4-oxadiazol como inibidor de histona desacetilase 6 e a composição farmacêutica que compreende os mesmos | |
| BR0316057A (pt) | Métodos de tratar, controlar ou prevenir um câncer especìfico e uma doença associada com angiogênese indesejada e de reduzir ou evitar um efeito adverso associado com a administração de um segundo ingrediente ativo e com a terapia de radiação, terapia hormonal, terapia biológica ou imunoterapia em um paciente sofrendo de um câncer especìfico, composição farmacêutica e kit | |
| PE20221168A1 (es) | Agonistas del receptor npy2 | |
| BR112022016743A2 (pt) | Compostos de derivado de 1,3,4-oxadiazol como inibidor de histona desacetilase 6 e a composição farmacêutica que compreende os mesmos | |
| BR112022008095A2 (pt) | Métodos e composições para o tratamento da síndrome de rett | |
| JP2019529569A (ja) | 整形外科疾患の治療のための組成物および方法 | |
| BR112022019486A2 (pt) | Agente terapêutico para infecção por coronavírus | |
| DeRossi et al. | Sedation and pain management with intravenous Romifidine− Butorphanol in standing horses | |
| CO2025007626A2 (es) | Composiciones farmacéuticas para administración ocular | |
| DiMarchi | “Let's Stay Together”; GIP and GLP-1 dual agonism in the treatment of metabolic disease | |
| BR112019024804A2 (pt) | compostos bicíclicos 5,6-fundidos e composições para o tratamento de doenças parasíticas | |
| MX2022005014A (es) | Combinacion de un antagonista de cxcr7 con un modulador del receptor s1p1. |